Category: Acadia Pharma

Is VistaGen The Next Big Winner In CNS?

I’ve been a stock analyst for a pretty long time – going on 16 years now. I’ve picked some big winners and some big losers. One thing I noticed, I seem to have better luck in CNS disorders than say, wound care! Acadia Pharmaceuticals, Auspex Pharma, Neurocrine Bio, and Cynapsus Therapeutics were all small-cap biopharma…

Will Third Time Be A Charm For Acadia Pharmaceuticals?

Investors familiar with Acadia Pharmaceuticals (ACAD, $1.28/share) know the company’s lead pipeline candidate, pimavanserin, a potent and selective 5-HT2A inverse agonist, failed the first phase 3 trial (Study -012) based on unusually high placebo response. When -012 failed, management discontinued the second phase 3 trial, Study-014, early. What Went Wrong? Upon detailed analysis of the…